References
1. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on
Rhinosinusitis and Nasal Polyps 2020. Rhinology . Feb 20
2020;58(29):1-464.
2. Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic
rhinosinusitis and their association with treatment outcomes.Allergy . 2018/07/01 2018;73(7):1459-1469.
3. Shah SA, Ishinaga H, Takeuchi K. Pathogenesis of eosinophilic chronic
rhinosinusitis. Journal of Inflammation . 2016/04/06
2016;13(1):1-9.
4. Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic
rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory
disease. American Journal of Respiratory and Critical Care
Medicine . 2015;192(6):682-694.
5. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of
chronic rhinosinusitis based on cluster analysis of biomarkers.Journal of Allergy and Clinical Immunology . May
2016;137(5):1449-1456.
6. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing
effect of mepolizumab in eosinophilic asthma. New England Journal
of Medicine . 2014;371(13):1189-1197.
7. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics
and pharmacodynamics of SB-240563, a humanized monoclonal antibody
directed to human interleukin-5, in monkeys. Journal of
Pharmacology and Experimental Therapeutics . 1999;291(3):1060-1067.
8. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab
add-on therapy on health-related quality of life and markers of asthma
control in severe eosinophilic asthma (MUSCA): a randomised,
double-blind, placebo-controlled, parallel-group, multicentre, phase 3b
trial. Lancet Respiratory Medicine . 2017;5(5):390-400.
9. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in
patients with severe eosinophilic asthma. New England Journal of
Medicine . 2014;371(13):1198-1207.
10. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe
eosinophilic asthma (DREAM): a multicentre, double-blind,
placebo-controlled trial. The Lancet . 2012;380(9842):651-659.
11. Kanda A, Kobayashi Y, Asako M, Tomoda K, Kawauchi H, Iwai H.
Regulation of interaction between the upper and lower airways in united
airway disease. Medical Sciences . Feb 11 2019;7(2):27-35.
12. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment
reduces deposition of ECM proteins in the bronchial subepithelial
basement membrane of mild atopic asthmatics. The Journal of
Clinical Investigation . 2003;112(7):1029-1036.
13. Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway
eosinophil numbers, but not their functional phenotype, in asthma.American Journal of Respiratory & Critical Care Medicine .
2017;196(11):1385-1395.
14. Walter S, Ho J, Alvarado R, et al. Effect of monoclonal antibody
drug therapy on mucosal biomarkers in airway disease: a systematic
review. Clinical & Experimental Allergy . 2020;50(11):1212-1222.
15. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in
severe nasal polyposis with mepolizumab: randomized trial. Journal
of Allergy and Clinical Immunology . 2017;140(4):1024-1031.
16. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a
humanized anti–IL-5 mAb, as a treatment option for severe nasal
polyposis. Journal of Allergy and Clinical Immunology .
2011;128(5):989-995.
17. Jeimy S, Lam G, Moote WD, Rotenberg B. Mepolizumab for severe
chronic rhinosinusitis with polyposis: a case report. Allergy,
Asthma and Clinical Immunology . 2017;14(1):92.
18. Snidvongs K, Lam M, Sacks R, et al. Structured histopathology
profiling of chronic rhinosinusitis in routine practice.International Forum of Allergy & Rhinology . 2012;2(5):376-385.
19. Van Es SL, Greaves J, Gay S, Ross J, Holzhauser D, Badrick T.
Constant quest for quality: digital cytopathology. Journal of
Pathology Informatics . 2018;9(13):1-6.
20. Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: open source
software for digital pathology image analysis. Scientific
Reports . 2017;7(1):16878.
21. Taqi SA, Sami SA, Sami LB, Zaki SA. A review of artifacts in
histopathology. Journal of Oral and Maxillofacial PathologyMay-Aug 2018;22(2):279-279.
22. Protheroe C, Woodruff SA, De Petris G, et al. A novel histologic
scoring system to evaluate mucosal biopsies from patients with
eosinophilic esophagitis. Clinical Gastroenterology and
Hepatology . 2009;7(7):749-755.
23. Bachert C, Gevaert P, Holtappels G, Johansson SGO, van Cauwenberge
P. Total and specific IgE in nasal polyps is related to local
eosinophilic inflammation. Journal of Allergy and Clinical
Immunology . 2001;107(4):607-614.
24. SPSS Statistics . IMB, Corporation; 2019.
25. GraphPad Prism GraphPad Software, Incorporation.; 2019.
26. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti–IL-5
(mepolizumab) therapy induces bone marrow eosinophil maturational arrest
and decreases eosinophil progenitors in the bronchial mucosa of atopic
asthmatics. Journal of Allergy and Clinical Immunology .
2003;111(4):714-719.
27. Sonoda Y, Arai N, Ogawa M. Humoral regulation of eosinophilopoiesis
in vitro: analysis of the targets of interleukin-3,
granulocyte/macrophage colony-stimulating factor (GM-CSF), and
interleukin-5. Leukemia . 1989;3(1):14-18.
28. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ.
Granulocyte/macrophage colony-stimulating factor and interleukin 3
release from human peripheral blood eosinophils and neutrophils.The Journal of Experimental Medicine . 1991;174(3):745-748.
29. Rothenberg ME, Owen WF, Silberstein DS, Soberman RJ, Austen KF,
Stevens RL. Eosinophils cocultured with endothelial cells have increased
survival and functional properties. Science .
1987;237(4815):645-647.
30. Schwartz C, Willebrand R, Huber S, et al. Eosinophil-specific
deletion of IκBα in mice reveals a critical role of NF-κB–induced
Bcl-xL for inhibition of apoptosis. Blood .
2015;125(25):3896-3904.
31. Farahi N, Singh NR, Heard S, et al. Use of 111-Indium–labeled
autologous eosinophils to establish the in vivo kinetics of human
eosinophils in healthy subjects. Blood . 2012;120(19):4068-4071.
32. Weller PF, Spencer LA. Functions of tissue-resident eosinophils.Nat Rev Immunol . 2017;17(12):746-760.
33. Ikeda K, Shiozawa A, Ono N, et al. Subclassification of chronic
rhinosinusitis with nasal polyp based on eosinophil and neutrophil.Laryngoscope . 2013;123(11):1-9.
34. Lam K, Schleimer R, Kern RC. The etiology and pathogenesis of
chronic rhinosinusitis: a review of current hypotheses. Current
Allergy Asthma Respiratory . 2015;15(7):41-50.
35. Ponikau JU, Sherris DA, Kephart GM, et al. Striking deposition of
toxic eosinophil major basic protein in mucus: implications for chronic
rhinosinusitis. Journal of Allergy and Clinical Immunology .
2005;116(2):362-369.
36. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and
function. Journal of Biological Chemistry .
2014;289(25):17406-17415.
37. Neves JS, Perez SAC, Spencer LA, et al. Eosinophil granules function
extracellularly as receptor-mediated secretory organelles.Proceedings of the National Academy of Sciences of the United
States of America . 2008;105(47):18478-18483.
38. Lal D, Wright BL, Shim KP, et al. Eosinophil peroxidase, GATA3, and
T-bet as tissue biomarkers in chronic rhinosinusitis. Journal of
Allergy and Clinical Immunology . 2019;143(6):2284-2287.
39. Rank MA, Ochkur SI, Lewis JC, et al. Nasal and pharyngeal eosinophil
peroxidase levels in adults with poorly controlled asthma correlate with
sputum eosinophilia. Allergy . 2016/04/01 2016;71(4):567-570.
40. Mukherjee M, Forero DF, Tran S, et al. Suboptimal treatment response
to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics
with airway autoimmune phenomena. European Respiratory Journal .
2020;56(4):2000117.
41. Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG.
Characterization of the relationship between dose and blood eosinophil
response following subcutaneous administration of mepolizumab.International Journal of Clinical Pharmacology and Therapeutics .
2015;53(12):1015-1027.
42. Skrgat S, Girandon Susanj P, Bidovec Stojkovič U, Korosec P.
Increase in systemic IL-5 is associated with mepolizumab treatment
failure in patients with severe asthma. European Respiratory
Journal . 2018;52(62):1132.
43. Tsukamoto N, Takahashi N, Itoh H, Pouliquen I. Pharmacokinetics and
pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal
antibody, in healthy Japanese male subjects. The American College
of Clinical Pharmacology . 2016;5(2):102-108.
44. Coffman RL, Brian WPS, Hudak S, Jackson J, Rennick D. Antibody to
interleukin-5 inhibits helminth-induced eosinophilia in mice.Science . 1989;245(4915):308-310.
45. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5-deficient mice have a
developmental defect in CD5+ B-1 cells and lack eosinophilia but have
normal antibody and cytotoxic T cell responses. Immunity .
1996;4(1):15-24.
46. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA.
Recombinant human interleukin 5 is a selective activator of human
eosinophil function. The Journal of Experimental Medicine .
1988;167(1):219-224.
47. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K.
Direct demonstration of delayed eosinophil apoptosis as a mechanism
causing tissue eosinophilia. The Journal of Immunology .
1997;158(8):3902-3908.
48. Mukherjee M, Lim HF, Thomas S, et al. Airway autoimmune responses in
severe eosinophilic asthma following low-dose Mepolizumab therapy.Allergy, Asthma & Clinical Immunology . 2017;13(1):2.
49. Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in
shaping type 2 immune responses. Cellular & Molecular
Immunology . 2019;1(1):1-11.
50. Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate
lymphoid cells control eosinophil homeostasis. Nature .
2013;502(7470):245-248.
51. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5
(mepolizumab) therapy reduces eosinophil activation ex vivo and
increases IL-5 and IL-5 receptor levels. Journal of Allergy and
Clinical Immunology . 2008;121(6):1473-1483.
52. Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies
as carrier proteins. Prolongation of in vivo effects of exogenous
cytokines by injection of cytokine-anti-cytokine antibody complexes.The Journal of Immunology . 1993;151(3):1235-1244.
53. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy
and safety of mepolizumab (SB-240563), a humanized monoclonal antibody
to IL-5, in cynomolgus monkeys. Journal of Allergy and Clinical
Immunology . 2001;108(2):250-257.
54. Zabeau L, Van der Heyden J, Broekaert D, et al. Neutralizing
monoclonal antibodies can potentiate IL-5 signaling. European
Journal of Immunology . 2001;31(4):1087-1097.
55. Terada N, Konno A, Natori T, Tada H, Togawa K. Interleukin-5
Preferentially Recruits Eosinophils from Vessels in Nasal Mucosa.Acta Oto-Laryngologica . 1993;113(506):57-60.
56. Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of
asthma-related hospitalization in mepolizumab studies of severe
eosinophilic asthma. Journal of Allergy and Clinical Immunology .
2017;139(4):1167-1175.
57. Blanchet M-R, McNagny KM. Stem cells, inflammation and allergy.Allergy, Asthma & Clinical Immunology . 2009;5(1):13-19.
58. DeMarcantonio MA, Han JK. Nasal polyps: pathogenesis and treatment
implications. Otolaryngologic Clinics of North America .
2011;44(3):685-695.
59. Saito H, Matsumoto K, Denburg AE, et al. Pathogenesis of murine
experimental allergic rhinitis: a study of local and systemic
consequences of IL-5 deficiency. The Journal of Immunology .
2002;168(6):3017-3023.
60. Pretolani M, Goldman M. IL-10: a potential therapy for allergic
inflammation? Immunology Today . 1997/06/01/ 1997;18(6):277-280.
61. Klion AD, Law MA, Noel P, Kim Y-J, Haverty TP, Nutman TB. Safety and
efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the
treatment of patients with hypereosinophilic syndrome. Blood .
2004;103(8):2939-2941.
62. Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of
dupilumab in moderate-to-severe atopic dermatitis: results from three
phase III trials. British Journal of Dermatology .
2020;182(5):1120-1135.
63. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after
cessation of mepolizumab therapy in severe eosinophilic asthma:
A 12-month follow-up analysis. Journal of Allergy and Clinical
Immunology . 2014;133(3):921-923.
64. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha
increases airway responsiveness and sputum neutrophilia in normal human
subjects. American Journal of Respiratory and Critical Care
Medicine . 1995;152(1):76-80.
65. te Velde AA, Huijbens RJF, Heije K, de Vries JE, Figdor CG.
Interleukin-4 (IL-4) inhibits secretion of IL-1β, tumor necrosis factor
a, and IL-6 by human monocytes. Blood . 1990;76(7):1392-1397.
66. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory
effects of interleukin 4: interleukin 4 suppresses interleukin 1
production but up-regulates gene expression and synthesis of interleukin
1 receptor antagonist. Proceedings of the National Academy of
Sciences of the United States of America . 1992;89(9):4076-4080.